Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]
3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance]
Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target raised by analysts at Stifel Nicolaus from $50.00 to $55.00. They now have a "hold" rating on the stock.
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 [Yahoo! Finance]
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back [Yahoo! Finance]